|Bid||96.81 x 900|
|Ask||97.59 x 800|
|Day's range||95.01 - 97.47|
|52-week range||75.25 - 129.29|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||62.61|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||29 Dec 1995|
|1y target est||N/A|
Neurocrine Biosciences ( NASDAQ:NBIX ) Full Year 2022 Results Key Financial Results Revenue: US$1.49b (up 31% from FY...
It hasn't been the best quarter for Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) shareholders, since the share price...
Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?